title: Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation.
authors.forename: Keiji
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mikoshiba
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
authors.forename: Hideki
authors.initials: H
authors.lastname: Akiyama
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
mesh_terms: D000328:Adult; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000008:administration & dosage* / Q000592:standards; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000628:therapy; D011743:Pyrimidines / Q000008:administration & dosage* / Q000592:standards; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate